Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Clin Cancer Res. 2009 Oct 13;15(21):6602–6608. doi: 10.1158/1078-0432.CCR-09-0829

Figure 4.

Figure 4

Patients with relapsed NB were treated subcutaneously every day for 5 days with recombinant human IFN-γ (0.1 mg/m2 per day). Tumor biopsies obtained prior to treatment and immediately after the 5-day treatment were evaluated by immunohistochemistry for expression of MHC class I and CD3. Results from 2 patients are shown (20X). Black arrows note examples of MHC class I-positive tumor cells; red arrows note CD3+ T cells.